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Summary Resistance to cytotoxics precludes the successful treatment of many solid tumours. Inhibition of
DNA synthesis in normal tissues with antimetabolites such as hydroxyurea (HU) may be a useful means of
improving the selective uptake of toxic thymidine analogues by the relatively resistant tumour cells. HU also
inhibits DNA repair by the critical depletion of intracellular deoxyribonucleotides. Twenty-five patients with
various malignancies received 5-iodo-2-deoxyuridine (IUdR) 100mgm-2 as a 20min i.v. infusion and the
uptake of IUdR was determined 1 h later immunocytochemically. Of these patients, 14 received IUdR 23 h
from the start of a continuous i.v. infusion of HU (36 g over 36 h). Uptake of IUdR was equally suppressed in
bone marrow and tumour aspirates, 0.1% ( ± 0.2%) of marrow precursor cells and 0.5% ( ± 0.4%) of tumour
cells respectively, in patients who received HU compared to the uptake of IUdR in 11 patients who were not
given HU 6.8% ( ± 1.1%) and 12.2% ( ± 1.8%) respectively. Mean HU plasma concentrations at the time of
IUdR administration was 1.7 ± 0.2 mM. The growth fraction of tumour cells (using Ki67 labelling) was not
changed after treatment with HU. It is concluded that (1) since DNA synthesis is effectively inhibited by HU
in tumour cells, differential uptake of radiolabelled IUdR by those cells will not be feasible using the current
schedule of HU administration, (2) HU may be used as an inhibitor of DNA repair in vivo since the degree of
inhibition correlates with that required to inhibit repair experimentally and that (3) Ki67 labelling index is not
useful in studying cell kinetics in patients treated with HU.
Drug resistance, either de novo or acquired, constitutes a
major barrier to the successful treatment of many solid
tumours (Goldie & Coldman, 1984). It has been proposed
that one way of overcoming drug resistance may be to
temporarily suppress DNA synthesis in bone marrow and
other normal tissues and then administer a cytotoxic nucleo-
tide which will be taken up preferentially by tissues in which
DNA synthesis has not been inhibited such as tumour DNA
(Bagshawe, 1986). This hypothesis is based on the assump-
tion that normal cells rarely develop resistance to antimeta-
bolite drugs, whilst cells from most solid tumours are either
resistant de novo or readily develop resistance following
exposure to antimetabolites. This proposed strategy was
termed 'Reverse Role Chemotherapy' (Bagshawe, 1986).
Initial experiments were undertaken using mice bearing hy-
droxyurea-resistant human tumour xenografts and showed
that pre-treatment of mice with hydroxyurea substantially
reduced the uptake of IUdR in normal cells but did not
significantly affect the uptake in tumour cells. Those results
suggested that DNA synthesis continued in tumour cells
when it was suppressed in normal renewal tissues (Bagshawe
et al., 1987). These results formed the basis for assessing
'Reverse Role Chemotherapy' in the treatment of human
tumours with cytotoxic nucleotides such as radiolabelled
IUdR.
Hydroxyurea is a rapidly acting ribonucleotide reductase
inhibitor (Lewis & Wright, 1974) which selectively inhibits
DNA synthesis by depleting the cellular deoxyribonucleotide
pools (Plagemann & Erbe, 1974). Despite its established
antileukaemic effect it displays little activity against solid
tumours (Kaung et al., 1968; Ariel, 1969). Hydroxyurea is a
cell cycle-specific cytotoxic and in order to achieve effective
DNA synthesis inhibition, it should be administered in a
schedule ensuring adequate and constant tissue concentra-
tions covering at least 1-2 cell cycle times. Veale et al. (1988)
established that the maximum tolerated dose of hydroxyurea
administered as a continuous i.v. infusion was 48 g over 48 h
and showed that at such dose levels it was possible to achieve
plasma concentrations (>1 mM) similar to the effective
inhibitory concentrations of hydroxyurea in vitro in sensitive
cell lines.
The process of excision repair of DNA damage plays a
major role in mammalian cells allowing effective removal of
lethal lesions in the DNA which may be induced by agents
directly damaging DNA such as platinum compounds and
alkylating drugs. At concentrations higher than 1 mM, hy-
droxyurea inhibits DNA repair synthesis by critical depletion
of intracellular purine deoxyribonucleotide pools. Unsched-
uled DNA synthesis appears to be less sensitive to inhibition
by hydroxyurea than replicative synthesis because the former
requires fewer deoxyribonucleotides (Snyder, 1984). Snyder et
al. (1984) have shown that hydroxyurea inhibits repair of
UV-irradiated confluent fibroblasts whereas cells in the log
phase showed no repair inhibition. This may be relevant to
the treatment of human solid tumours, the majority of which
possess a low growth fraction.
IUdR is a synthetic thymidine analogue that is taken up
by proliferating cells during the S-phase. It is phosphorylated
by thymidine kinase and incorporated into newly synthesised
DNA. Incorporated IUdR enhances radiosensitivity (Fornace
et al., 1990) and is potentially lethal when labelled with
radioactive iodine (Bloomer & Adelstein, 1978). However,
IUdR administered systemically to patients has been assoc-
iated with significant toxicity (Calabresi et al., 1961; Kinsella
et al., 1985) because of its uptake by normal proliferating
cells (Speth et al., 1989).
Begg et al. (1988) have shown that the cell-cycle distribu-
tion in solid tumours can be determined following a single
i.v. dose of IUdR. The proportion of cells taking up IUdR
represents cells which are in the S-phase of the cell cycle. It is
also possible to determine the percentage of S-phase cells by
incubating cells with IUdR or BUdR in vitro which correlates
well with in vivo labelling (Kamata et al., 1989). Similarly,
the growth fraction of tissues can be determined by immuno-
staining with Ki67, which is a nuclear antigen expressed only
in cycling cells (Gerdes, 1985).
The aim of this study was to extend the initial observation
of Bagshawe et al. (1987) in nude mice to man. Solid
tumours in man are intrinsically resistant to hydroxyurea and
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the only conventional use of hydroxyurea is in the treatment
of chronic myelogenous leukemia. For this purpose we have
taken fine needle aspirate biopsy specimens of tumour and
normal bone marrow from patients with various advanced
solid tumours. These samples were studied in order to (1)
determine the influence of hydroxyurea on the uptake of
IUdR by bone marrow and tumour cells, (2) identify any
selectivity for tumour cells and to (3) study the influence of
hydroxyurea on the Ki67 labelling index.
Materials and methods
Patients
There were 25 patients with advanced biopsy proven solid
tumour malignancies of whom 14 received hydroxyurea by
an intravenous infusion. Histological and treatment details of
the patients who received hydroxyurea are shown in Table I.
The mean age of the patients in the hydroxyurea group was
60.3 years (M:F, 4:10) and that of the non-hydroxyurea
group 57.3 years (M:F, 8:3). The 11 patients who did not
receive hydroxyurea had various malignancies and received
different chemotherapeutic agents. Previous chemotherapy
had been received by six patients in the hydroxyurea group
and three in the non-hydroxyurea group but none had been
treated previously with hydroxyurea. Approval to conduct
this study was granted by the Central Oxford Research
Ethical Committee (COREC) and informed consent was
obtained from each patient prior to entry into the study.
Hydroxyurea
Patients were undergoing treatment with hydroxyurea as part
of a treatment protocol combining hydroxyurea with cis-
platin, carboplatin, or dacarbazine (DTIC). Hydroxyurea
(Hydrea, Bristol-Myers Squibb, USA) was administered in a
dose of 36 g over 36 h via a controlled continuous in-
travenous infusion. Six patients received cisplatin 50-75 mg
m_2, four patients received carboplatin the dose (in mg)
calculated by a formula (5 x (glomerular filtration rate +
25)), and four patients were given dacarbazine (DTIC)
1.0 g m-2. All drugs were given by intravenous infusion 24 h
after commencing hydroxyurea infusion. Treatment cycles
were repeated every 3-4 weeks.
IUdR
5-iodo-2-deoxyuridine (Lyon and Brandfield Limited, Lon-
don, UK) was given in a dose of 100 mg m2 in I litre of
dextrose 5% infused i.v. over 20 min, 23 h from the start of
the hydroxyurea infusion and prior to the administration of
either cisplatin, carboplatin or dacarbazine. IUdR was ad-
ministered prior to any chemotherapy in the non-hydroxy-
urea group. IUdR was prepared by dissolving the powder in
dimethylsulfoxide (BDH, Poole, UK) to achieve a concentra-
tion of 35% and then filtering it through a 0.2 itm filter into
500ml of 5% dextrose.
Tumour and bone marrow aspiration
Tumour aspirates were obtained prior to starting treatment
and 1 h from the start of the IUdR infusion. Bone marrow
aspirates were obtained within 5 min of the tumour aspirates.
All aspirates were performed between 10.00 and 12.00 am to
avoid diurnal variation in DNA synthesis.
Material from superficial tumour deposits or pleural/ascitic
fluids was obtained using a 21 gauge hypodermic needle
attached to a 10ml syringe. Sternal puncture and aspiration
was performed using a 22 gauge x 1.5 inch paediatric lumbar
puncture needle (Yale Spinal, Becton Dickinson, Spain)
attached to a 10 ml syringe obtaining 0.5 ml of aspirate. All
aspirates, except effusions, were placed in 5 ml of RPMI 1640
(Gibco, Paisley, Scotland) contained in a heparinised tube.
Cellpreparation and stainingprotocol
Thick specimens were washed by centrifugation and re-
suspension in fresh RPMI 1640 culture medium (Gibco,
Paisley, Scotland). Cells were counted and reconstituted in
fresh medium at a final concentration of approximately one
million cells per ml. Aliquots of 1-2 ml were used for
incubation with IUdR. Prior to any immunocytochemistry
cells were cytocentrifuged at 550 g for 5 min. Cytocentrifuged
preparations were left to air dry overnight before being fixed
for 10 min in acetone at room temperature and stored
wrapped in aluminium foil at - 20°C. In vitro IUdR labelling
was performed by incubating the cell suspension with IUdR
at a final concentration of 10 tLM. Cultures were incubated at
37°C for 60 min and then cytocentrifuged.
Immunocytochemistry was performed using the mouse
monoclonal antibody BU20a (DAKO PATTS A/S, Glostrup,
Denmark) which recognises both IUdR and BUdR in the
DNA and anti-Ki67 monoclonal antibodies (DAKO PATTS
A/S, Glostrup, Denmark). The APAAP (alkaline phospha-
tase and monoclonal anti-alkaline phosphatase) immunoen-
zymatic technique of Cordell et al. (1984) was employed.
New Fuchsin (BDH, Poole, UK) was used as the substrate
for the reaction. DNA was denatured prior to staining with
BU20a in order to allow the expression of the nuclear
antigen. This was done by placing the slides in formamide
solution diluted to 95% with sodium salt citrate (SSC) for
40 min at 70°C. Stained slides were mounted using a water
based mounting medium DAKO glycergel Code No C563
(DAKO PATTS A/S, Glostrup, Denmark).
Table I Characteristics and treatment outcome of 14 patients who received hydroxyurea plus cisplatin, carboplatin or dacarbazine
Previous
No Age/Sex Diagnosisa Chemo Chemob Responsec
I 56/F Ovarian adenocarcinoma Y HU/CDDP PD
2 50/F Ovarian adenocarcinoma N HU/CDDP CR
3 59/F Ovarian adenocarcinoma Y HU/CARBOP PD
4 70/F Breast adenocarcinoma Y HU/CDDP PD
5 60/F Adenocarcinoma UO Y HU/CARBOP PD
6 62/F Adenocarcinoma UO N HU/CARBOP CR
7 71/F Adenocarcinoma UO N HU/CARBOP PD
8 73/M Malignant melanoma N HU/DTIC PR
9 29/M Malignant melanoma N HU/DTIC PD
10 65/F Malignant melanoma N HU/DTIC PD
11 59/F Malignant melanoma Y HU/CDDP PD
12 59/M Malignant melanoma N HU/DTIC PD
13 64/M Penile squamous cell ca N HU/CDDP PD
14 67/F Angiosarcoma Y HU/CARBOP PD
aUO, unknown orign. bChemo, chemotherapy; CDDP, cisplatin; CARBOP, carboplatin; DTIC, dacarbazine. CPD, progressive disease; CR,
complete remission; PR, partial remission; SD, stable disease.646 P.A. PHILIP et al.
Determination ofthe IUdR and Ki67 labelling indices (LI) in
tumour and bone marrow aspirates
A minimum of 500 malignant cells or BM precursor cells
were counted and the percentage of tumour and bone mar-
row cells which were stained with either BU20a or Ki67
monoclonal antibodies calculated. Samples with too few cells
were discarded.
Determination ofthepercentage uptake ofIUdR by cultured
cells in vitro at increasing IUdR concentrations
Cells from the human melanoma cell line A2058 which were
in exponential growth were incubated with IUdR for 1 h.
The final concentration of IUdR in the incubate ranged from
100f4M to 10 nM. Percentage of cells labelled with IUdR was
determined as described above.
Table II Hydroxyurea (HU) concentrations in plasma determined
in ten patients, 6 and 23 h from the start of a continuous i.v.
infusion at a rate of I g per h
HU concentrations (mM)
Patient 6h 23h
2 1.33 1.87 (1.89)
3 1.25 1.84 (1.96)
6 0.89 1.37
7 0.87 2.13 (1.51)
8 1.26 2.81
9 1.24 2.12
10 1.04 1.26
1 1 1.0 2.01
13 0.67 1.18
14 0.97 0.84
Mean (+s.e.) 1.1 ± 0.1 1.7 ± 0.2
P value <0.005
Values in parentheses indicate concentration in ascitic fluid.
Hydroxyurea plasma and asciticfluid concentrations
Ten ml of venous blood was collected from ten patients into
a heparinised tube 0, 6 and 23 h from the start of the
hydroxyurea infusion. Ten ml of ascitic fluid was also
aspirated 23 h from the start of the hydroxyurea infusion in
three patients. Plasma was immediately separated by centri-
fugation and stored at - 20°C pending analysis. The assay of
hydroxyurea in plasma and ascites was undertaken using the
standard colourimetric method described by Fabricus and
Rajewsky (1971).
Statistical analysis
The paired two-tailed t-test was employed to compare two
samples using StatView 512 + software package on an Apple
Macintosh SE personal computer. Statistical significance was
taken at a P value of < 0.05.
Results
Relationship between increasing concentration ofIUdR and
percentage oflabelled A2058 cells
Figure 1 shows the percentage of labelled cells over a range
of IUdR concentrations between 100jAM and 10 nM. The
maximum percentage of labelled cells was at concentrations
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of 10JAM and 10 JAM. A fall in the IUdR concentration by at
least two logs below 10 JAM resulted in complete absence of
staining with anti-IUdR antibodies.
Concentrations ofhydroxyurea in plasma and asciticfluid
Mean (± s.e.) 6 and 23 h plasma hydroxyurea concentrations
were 1.1 ± 0.1 and 1.7 ± 0.2 mM respectively (Table II). Con-
centrations at 23 h were higher (P<0.005) than those achie-
ved after 6h of i.v. infusion and very similar to the 24 h
concentration of hydroxyurea reported by Veale et al. (1988)
using a similar rate of hydroxyurea infusion. Concentrations
of hydroxyurea in ascitic fluid were comparable to those
levels achieved in plasma (1.9, 2.0 and 1.5 mM) indicating
adequate penetration of hydroxyurea into ascitic fluid.
In vitro uptake ofIUdR by tumour cells
The mean (± s.e.) percentage of labelled cells by in vitro
incubation with IUdR prior to any chemotherapy was similar
in the non-hydroxyurea and hydroxyurea arms of the study
(6.1 ± 1.6% and 5.9 ± 0.8% respectively, P>0.4).
.
.
.
100
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Figure 1 Cells from A2058 cell line grown in the exponential phase were incubated with increasing concentrations of IUdR (0.01-100I1M). Values on the Y axis represent percentages of the maximum labelling index achieved in this experiment.
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Comparison ofin vitro and in vivo uptake ofIUdR by tumour
cells
In the group of patients not receiving hydroxyurea, incor-
poration of IUdR into tumour cells was determined in vitro
before and in vivo after administering IUdR in order to
assess whether there was any significant difference in the
IUdR labelling index using either method. The percentage of
in vitro IUdR labelled tumour cells (6.1 ± 1.6%) was not
statistically different (P> 0.1) from the percentage of labelled
cells following i.v. administration of IUdR (6.8 ± 1.1%)
(Table III). The Ki67 LI of tumour cells before and after the
administration of IUdR was again not significantly different
(13.4 ± 2.9% and 14.1 ± 2.6%; P>0.4).
In vivo uptake ofIUdR by tumour cells before and after
hydroxyurea
The mean ( ± s.e.) percentage of tumour cells labelled with
BU20a in patients not treated with hydroxyurea was 6.8 +
1.1% with a range of 4-13% (Table III). The mean (± s.e.)
percentage of labelled tumour cells in the hydroxyurea
treated group was 0.5 ± 0.4% (Table IV; P<0.0005). There
was detectable incorporation of IUdR in tumour cells from
only three patients treated with hydroxyurea with a mean
percentage of labelled cells of 2.4% and no detectable incor-
poration of IUdR (0%) in the rest of the patients. The IUdR
labelling index did not change in one patient (No. 3) follow-
ing treatment with hydroxyurea.
Influence ofhydroxyurea on Ki67 labelling index (LI) of
tumour cells
The mean ( ± s.e.) percentage of tumour cells labelled with
Ki67 antibody determined prior to hydroxyurea administra-
tion and approximately 24 h from the start of the hydroxy-
urea infusion was similar (Table IV) (14.1 ± 1.5% and
13.0 ± 1.4% respectively, P>0.1).
In vivo incorporation ofIUdR and Ki67 labelling index of
bone marrow cells before and after hydroxyurea
The mean ( ± s.e.) percentage of marrow prescursor cells
taking up IUdR in ten patients who did not receive hydroxy-
urea was 12.2 ± 1.8% with a range of 2-22% (Table III),
whereas in the nine patients who were treated with hydroxy-
urea the mean percentage of labelled bone marrow precursor
cells was significantly reduced (0.1 ± 0.1%, P<0.0005)
(Table IV). BM aspiration was not feasible from 3 patients
and the samples from another three patients were not
satisfactory. The Ki67 labelling index was slightly reduced
following treatment with hydroxyurea (18.8% vs 15.6%
respectively, P> 0.05).
Table III IUdr and Ki67 labelling index of tumour and bone marrow aspirates
determined in 11 patients following treatment with i.v. IUdR 100mgm2 only
Labelling index (%)
Pre-IUdRITumour Post-lUdRITumour Post-IUdR/BM
(in vitro) (in vivo) (in vivo)
No Ki67 BU20a Ki67 BU20a Ki67 BU20
15 ND ND ND ND 18.0 14.5
16 ND ND ND ND 19.5 9.0
17 12.5 7.0 11.0 6.5 25.0 22.0
18 18.0 9.9 16.5 13.0 10.0 2.0
19 5.0 2.0 15.0 7.0 24.0 10.0
20 14.5 5.5 10.0 5.5 17.0 16.0
21 NC NC NC NC 19.0 16.0
22 27.5 13.0 25.0 7.0 17.0 6.0
23 6.0 2.5 7.0 4.0 20.0 15.0
24 10.0 3.0 NC 4.5 ND ND
25 NC NC NC NC 18.0 11.0
Mean (±s.e.) 13.4±2.9 6.1 ± 1.6 14.1 ±2.6 6.8 ± 1.1 18.8 ± 1.3 12.2 ± 1.8
ND, aspiration not performed; NC, inadequate cell count. Pre-treatment tumour
samples were also obtained and incubated with IUdR 1OLM.
Table IV IUdR and Ki67 labelling index of tumour and bone marrow (BM)
aspirates in 14 patients who received a continuous i.v. infusion ofhydroxyurea (1 g
per h)
Labelling index (%)
Pre-HU/Tumour Post-HUITumour Post-HU/BM
(in vitro) (in vivo) (in vivo)
No Ki67 BU20a Ki67 BU20a Ki67 BU20
1 12.2 6.5 10.0 0 10.0 0
2 11.0 1.5 8.0 0 NC NC
3 9.5 4.9 10.0 5 ND ND
4 21.0 10.0 20.0 0 22.0 0
5 15.0 10.0 10.0 2.0 25.0 0
6 18.0 9.9 15.0 0 18.0 0
7 ND ND 20.0 0 NC NC
8 12.5 6.0 PS 0 10.0 0
9 14.0 4.0 9.0 0 14.0 0
10 17.0 5.0 18.0 0.1 16.0 0
11 24.2 4.7 15.0 0 15.0 0
12 7.0 3.0 5.0 0.0 ND ND
13 ND ND 18.5 0 NC NC
14 9.5 5.0 10.0 0 10.0 0.5
Mean (+s.e.) 14.2± 1.5 5.9±0.8 13.0± 1.4 0.5 ±0.4 15.6± 1.8 0.1 ±0.1
ND, aspiration not performed; NC, inadequate cell count; PS, poor staining.
Pre-treatment tumour aspirates were also obtained and incubated with IUdR
1O tM for I h.648 P.A. PHILIP et al.
Response to treatment
Details of tumour response to hydroxyurea based chemo-
therapy are shown in Table I. Patients received a mean
number of 3.3 courses with a range of 1-6. Standard criteria
were applied to determine response to treatment. One patient
with ovarian adenocarcinoma with ascites and an abdominal
mass and another with adenocarcinoma of unknown origin
presenting with ascites achieved durable (10 months and 19
months) complete remission after receiving six courses of
hydroxyurea with cisplatin and hydroxyurea with carboplatin
respectively. One other patient with malignant melanoma
achieved a partial remission in cutaneous metastases which
lasted for approximately 4 months.
Discussion
This study shows that hydroxyurea significantly inhibited the
IUdR incorporation by bone marrow and tumour cells
through the inhibition of DNA synthesis. Mean plasma and
ascitic fluid hydroxyurea concentrations of greater than 1 mM
were achieved which were similar to effective inhibitory con-
centrations in appropriate in vitro models. Belt et al. (1980)
described an intravenous schedule delivering a lower rate
(approximately 1/3) of hydroxyurea compared to the present
study and showed that there was no appreciable effect on the
uptake of radiolabelled thymidine in bone marrow and
tumour cells after 72 h of continuous infusion. It is probable
that their technique of in vitro incubation with radiolabelled
thymidine for the estimation of the S-phase washed out the
hydroxyurea from cells resulting in the removal of its inhi-
bitory effect. In our study, hydroxyurea significantly inhibited
the synthesis of DNA in tumour cells despite the fact that
mean cell-cycle times in those cells are expected to be
significantly longer (Wilson et al., 1988) than the 23 h
exposure period to hydroxyurea. Threshold cytostatic and
cytotoxic concentrations have been suggested (Timson, 1969)
and it has been shown that a concentration of 1 mM of
hydroxyurea will effectively inhibit DNA synthesis in most
experimental systems (Sinclair, 1965).
The optimum concentration of IUdR for in vitro incuba-
tion (10 LM) was based on the predicted range of plasma
concentrations of IUdR (Hoshino et al., 1985). The percen-
tage of cells labelled by IUdR in the A2058 cell line was
shown to be constant at concentrations of 10gM and 100gM.
A 2-log decrease in IUdR concentration resulted in complete
loss of immunocytochemical detection of IUdR incorpora-
tion by those cells. It may thus be infered that the degree of
DNA synthesis inhibition detected in the majority of tumour
cells and bone marrow following treatment with hydroxyurea
was at least in the order of 2 logs.
Previous clinical trials have concluded that solid tumours
respond poorly to hydroxyurea. Consequently hydroxyurea,
especially as single agent, is not included in the conventional
systemic therapy of such tumours. The principal biochemical
target of hydroxyurea is ribonucleotide reductase which is a
key enzyme in de novo DNA synthesis. Altered expression of
ribonucleotide reductase due to gene amplification has been
suggested as a mechanism of resistance to hydroxyurea in
certain cell lines (Wright, 1987). This study was designed to
assess in vivo biochemical effects of high dose hydroxyurea
and most patients had tumours which were considered resis-
tant to conventional chemotherapy. IUdR incorporation was
effectively suppressed in 11 of the 14 cases treated with
hydroxyurea but only three of the 14 patients showed objec-
tive evidence of tumour response.
Bagshawe et al. (1987) demonstrated that hydroxyurea
pre-treatment of mice bearing human tumour xenografts
which were known to be resistant to hydroxyurea resulted in
a reduction of the uptake of radiolabelled IUdR by normal
cells without a concomitant decrease in the incorporation of
IUdR by the tumours cells. The results of our study show
that hydroxyurea inhibits the incorporation of IUdR by the
tumour cells indicating that clinical resistance to hydroxyurea
should not be equated with resistance to hydroxyurea at the
cellular level. Determination of biochemical parameters, such
as the IUdR labelling index, will therefore not predict the
eventual outcome of treatment with hydroxyurea or other
similar drugs.
The schedule of hydroxyurea administration in our study
was different from that employed by Bagshawe et al. which
employed bolus administrations of hydroxyurea rather than
continuous infusion. In their study uptake of IUdR was
determined by autoradiography using ['25f]-labelled IUdR.
The different outcome between the two studies is probably
due to the variable drug susceptibility between different tis-
sues as a consequence of different threshold values of
hydroxyurea plasma inhibitory concentrations to tumour and
BM cells. It is also possible that tumour xenografts inves-
tigated by Bagshawe et al. (1987) were more resistant to
hydroxyurea than the tumours in our study.
The higher values for the Ki67 labelling index compared to
the percentage labelled cells with BU20a is because Ki67
antigen is expressed in cells throughout the cell cycle whereas
IUdR labelled cells are those only in the S-phase. The
absence of any significant change in Ki67 labelling index of
tumour and BM cells is compatible with the synchronisation
of the cells by hydroxyurea at the GI/S interphase. This is
explained by the fact that Ki67 antigen is expressed by all
phases of the cell cycle and hydroxyurea treated cells will be
blocked at GI/S interphase. Ki67 labelling will therefore be
not helpful in studying cell kinetics following treatment with
antimetabolites.
This work however shows that it is possible to study in
vivo the acute influence of systemic treatment on DNA syn-
thesis in normal and tumour cells. This may provide an
excellent model for insight into the pharmacological action of
those drugs allowing the design of rational schedules of
therapy. Conventional methods of bone marrow aspiration
are not routinely incorporated into *research protocols be-
cause of the degree of discomfort incurred on patients. The
procedure used in this study resulted in little or no discom-
fort to patients because of the small needle size. The use of
immunocytochemistry to obtain information regarding the
S-phase fraction and growth fraction of tumour and bone
marrow may provide a quick method to monitor therapy and
modify treatment within a reasonably short space of time.
Hydroxyurea effectively inhibits DNA synthesis in tumour
cells in vivo and based on the results of uptake of IUdR in
the A2058 cell line it can be assumed that >99% inhibition
in DNA synthesis was seen in bone marrow and tumour
cells. It is possible that employing a lower level of inhibition
of hydroxyurea may favourably produce a differential inhibi-
tion of DNA synthesis in BM and tumour cells and allow the
selective uptake of IUdR by tumour cells. Nevertheless, it
was possible to achieve plasma concentrations of hydroxy-
urea close to levels which are inhibitory to DNA repair in
vitro (Snyder, 1984). This study forms the basis of our cur-
rent schedule of hydroxyurea to inhibit repair of cisplatin-
DNA adducts using a loading schedule of administration
followed by a longer maintenance infusion relative to the
administration of the DNA damaging agent.
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